Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is thought to exert its effects by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure types and anxiety disorders, but evidence and dosing may vary.
## Adult Dosing
* **Lennox-Gastaut Syndrome:**
* Initiate at 5 mg twice daily (BID).
* Increase dose by 5-10 mg every week based on clinical response and tolerability.
* Maximum dose: 10 mg BID (total 20 mg/day).
## Pediatric Dosing (2 years and older)
* **Lennox-Gastaut Syndrome:**
* Initiate at 5 mg BID.
* Increase dose by 5-10 mg every week based on clinical response and tolerability.
* Maximum dose: 10 mg BID (total 20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, but specific guidelines are limited.
* **Renal Impairment:** Use with caution. Dose adjustment may be needed, particularly in severe impairment.
* **Concomitant Medications:** Dose reduction may be required when used with other CNS depressants or CYP2C19 inhibitors.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Sleep apnea syndrome.
## Adverse Effects
* **Common:** Somnolence, drooling, constipation, decreased appetite, vomiting, diarrhea, fatigue, aggression, irritability, upper respiratory tract infection.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, respiratory depression, cognitive impairment, paradoxical reactions (agitation, hostility), withdrawal symptoms. Clobazam is a Schedule IV controlled substance.
## Key Drug Interactions
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam levels, requiring dose reduction.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels, requiring dose increase.
* **CNS Depressants (e.g., alcohol, opioids, sedatives):** Additive CNS depression; increased risk of sedation, respiratory depression.
* **Antiepileptic Drugs (AEDs):** Potential for altered efficacy or increased adverse effects; monitor closely.
## Monitoring
* **Seizure frequency and type:** Assess efficacy and potential for breakthrough seizures.
* **CNS adverse effects:** Monitor for somnolence, dizziness, confusion, and cognitive impairment.
* **Respiratory status:** Especially when combined with other respiratory depressants.
* **Skin reactions:** Educate patients and caregivers to report any rash immediately.
* **Signs of withdrawal:** If abrupt discontinuation is being considered (tapering is essential).
* **Therapeutic drug monitoring (TDM):** While not routinely recommended, TDM may be considered in cases of suspected non-adherence, toxicity, or altered metabolism.
## Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, potentially allowing for once or twice-daily dosing.
* Metabolized by CYP2C19, which exhibits significant genetic polymorphism; consider potential for altered metabolism.
* Do not abruptly discontinue clobazam due to the risk of withdrawal seizures. Tapering is crucial.
* Educate patients and caregivers on the risks of somnolence and CNS depression, especially when initiating therapy or increasing the dose.
* Be aware of the potential for serious skin reactions and advise immediate discontinuation and medical attention if a rash develops.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace comprehensive drug information resources. Always consult the current prescribing information and relevant clinical guidelines before initiating or modifying therapy.*
